Sweden approves generic copy of GSK's top lung drug

LONDON Tue Jan 14, 2014 7:37am EST

LONDON Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair.

Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Swedish authorisation for its generic version of the drug, known as AirFluSal Forspiro.

The initial Danish green light was given to the product in December.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.